Clinical Edge Journal Scan

Rates of relevant counseling/education lower at dermatology vs. primary care PsA outpatient visits


 

Key clinical point: The chances of counseling or education for modifiable lifestyle risk factors were rare during psoriatic arthritis (PsA) or psoriasis outpatient visits, with rates being even lower among dermatologists compared to nondermatologists.

Major finding: Overall, low rates of counseling were observed for any modifiable lifestyle risk factor (11.1%; 95% CI 7.9%-15.3%), tobacco (4.8%; 95% CI 2.8%-8.0%), and obesity (2.8%; 95% CI 1.7%-4.5%). Moreover, counseling rates for any modifiable risk factor were lower for dermatologists compared to nondermatologists visits ( 0.9% vs. 22.6%; P < .001).

Study details: This study used the National Ambulatory Medical Care Survey (2002-2016) and the National Hospital Ambulatory Medical Care Survey (2002-2011) conducted in the United States to assess the frequency of education/counseling for modifiable risk factors in an estimated 41.8 million psoriasis or PsA outpatient visits .

Disclosures: Dr. Barbieri is supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health and receives partial support from Pfizer. The authors declared no conflicts of interest.

Source: Taylor MT et al. J Am Acad Dermatol. 2021 Aug 24. doi: 10.1016/j.jaad.2021.08.034 .

Recommended Reading

Calcipotriol-betamethasone more effective than calcipotriol alone in treating plaque psoriasis
MDedge Dermatology
Impact of psoriasis on clinical outcomes in patients with pulmonary embolism
MDedge Dermatology
Clobetasol propionate 0.025% is a safe treatment option for moderate-to-severe psoriasis
MDedge Dermatology
Abdominal subcutaneous adipose tissue elicits sex-specific effects on coronary atherosclerosis in psoriasis
MDedge Dermatology
Secukinumab therapy against plaque psoriasis yields high patient satisfaction
MDedge Dermatology
Psoriasis exhibits a strong causal relationship with psychiatric diseases
MDedge Dermatology
Proton pump inhibitors likely promote psoriasis development
MDedge Dermatology
European agency recommends two new adalimumab biosimilars
MDedge Dermatology
Risk of developing PsA significantly lower in psoriasis patients treated with biologics
MDedge Dermatology
Affected body surface area predicts risk of PsA in patients with psoriasis
MDedge Dermatology